Skip to content

Vagus Stimulation in Female Long COVID Patients.

Effects of Transcutaneous Electrical Neurostimulation on Female Patients With Long COVID - a Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05918965
Acronym
Vagus
Enrollment
45
Registered
2023-06-26
Start date
2023-03-22
Completion date
2025-03-01
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID, Long Covid19, Post COVID-19 Condition, Post-COVID-19 Syndrome, Post COVID Condition, Post-COVID Syndrome, Vagus Nerve Diseases

Keywords

auricular transcutaneous electrical vagal nerve stimulation, TENS

Brief summary

The aim of the present pilot study is to investigate the acceptance, feasibility and implementation of the vagus nerv stimulation in Long COVID patients. Additionally, the effects on parameters of the autonomic nervous system as well as on symptoms of Long COVID will be described in a pre/post comparison. For this purpose, a total of 45 female Long COVID patients will participate in the randomized controlled pilot study. Patients will perform auricular vagus stimulation daily for 12 weeks. The patient collective will be randomized into three groups (A: 10 hertz, B: 25 hertz, C: 2 hertz=control group). If appropriate results are obtained, further adequately powered intervention studies are planned.

Detailed description

Patients start on day 0, when the first assessment takes place. This consists of a medical diagnostic interview and sociodemographic, anthropometric, medical and functional data are collected (for a detailed description, see chapter 5. Statistics). Subsequently, the patients fill out the given questionnaires (paper/pencil version), which are then evaluated. Subsequently, the test persons are trained by a doctor how the electrical stimulation works with a demo device. Finally, the device is taken over by the company Schwa-Medico. The whole first assessment lasts about 2 hours and always takes place from 8 a.m. at constant room temperature (22-23 C°). The outcome parameters are recorded before the start of the vagus nerve stimulation (T0), during the treatment after 4 weeks (T0+4Wo) and after a total of 12 weeks (T0+12Wo) after the end of the therapy. Which assessments are collected at the different time points is listed in the biometry section. The assessments are performed by physicians of the Department of Physical Medicine, Rehabilitation and Occupational Medicine. All assessments take place at relatively the same time, at constant room temperature (22-23 C°). The patients have to appear fasting. T0: Medical history, examination, randomization, pre-tests, enrollment. T0+4Wo: Intermediate examination T0+12Wo: final examination, post-tests, return of device This pilot study investigates the acceptability, feasibility, and implementation of the VNS measure in Long COVID patients. In addition, effects on autonomic nervous system parameters (heart rate, blood pressure, rate pressure product, heart rate variability = HRV, cortisol in saliva), on symptoms fatigue, dyspnea as well as health-related quality of life (HRQOL) are described: Time points: T0, T0+4wk, T0+12wk. Parameters - collected at relatively the same time each day, at constant room temperature (22-23 C°): * Documentation of blood pressure and pulse rate: by means of Boso Medicus (Bosch + Sohn GmbH u. Co. KG, Jungingen, Germany), calculation of the so-called rate pressure-product (syst. blood pressure x heart rate) * Heart rate variability * Salivary cortisol * Fatigue: Brief Fatigue Inventory (BFI) * Health-related quality of life (HRQOL): SF-36 (short form) questionnaire instrument * Dyspnea: Modified Borg Scale * Sleep: Insomnia Severity Index (ISI)

Interventions

DEVICEtranscutaneous electrical vagal neurostimulation

daily for 12 weeks

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Female patients with Long COVID (history, physical examination, findings) * age 18-70 years * signed informed consent

Exclusion criteria

* Hearing aid implants (cochlear implants) * surgical transection of the vagus nerve * Malignancies * autoimmune diseases * orthopedic diseases * rheumatological diseases * neurological diseases * postoperative, fresh injuries to the ear * febrile diseases * inflammations * psychiatric diseases * pacemakers * implanted cardioverter and defibrillators (ICDs) * seizure disorders * Meniere's disease * negative experience with electrotherapy * insufficient knowledge of the German language

Design outcomes

Primary

MeasureTime frameDescription
Heart rate variability3 times for 12 weeks20-minute documentation of the heart rate variability with a 24-hour-elektrocardiography

Secondary

MeasureTime frameDescription
Saliva cortisol3 times for 12 weeksin the morning until the latest 10am
Questionnaire Brief Fatigue Inventory (BFI)3 times for 12 weeksFatigue evaluation
Questionnaire Short form (SF)-363 times for 12 weeksHealth related quality of life evaluation
blood pressure and pulse3 times for 12 weeksvia Boso Medicus plus their mutiplication for the rate-pressure-product
Questionnaire Insomnia Severity Index (ISI)3 times for 12 weeksSleep evaluation
Post-COVID-19 Functional Status scale (PCFS)3 times for 12 weeksGrade 0-4
Questionnaire Borg-Scale3 times for 12 weeksDyspnea evaluation

Countries

Austria

Contacts

Primary ContactVeronika Helbich-Poschacher, M.D.
veronika.helbich-poschacher@meduniwien.ac.at+4314040043300
Backup ContactMohammad Keilani, M.D.
mohammad.keilani@meduniwien.ac.at+4314040043300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026